.alpha.1b-adrenergic receptor antagonists
CA 2341542 A1 · Owner: Isogaya, Masafumi · Inventors: Moriwaki, Mitsuhiro; Ohmori, Eiji; Kumagai, Hiroki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of the general formula (I) or pharmacologically acceptable acid addition salts thereof; and .alpha.1B-adrenergic receptor antagonists comprising the compounds or the salts: wherein Ar is indole or the like; R1 is hydrogen or the like; B is a bond or B-N-R1 may form a ring structure such as piperidine; n is 0, 1 or the like; A is trimethylene butylene, or the , like; and Q is piperidine isoindoline, or the like. The compounds and the salts serve as antagonists having a high affinity for .alpha.1B-adrenergic receptor and are useful as drugs to be used in the prevention and/or treatment of .alpha.1B-adrenergic receptor-related diseases (such as hypertension) or as …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 22, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 22, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 22, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.